AI assistant
Medivir Share Issue/Capital Change 2026
3177_rns_2026-02-09_f42d1b2a-a9dd-4b21-82a8-7770da06fc4d.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
{0}------------------------------------------------
Medivir announces the outcome of the directed share issue which was announced on 5 February 2026
90,000,000 ordinary shares were issued, and all shares have been subscribed for by and allotted to Carl Bennet AB in accordance with the resolution regarding the share issue.
The subscription price was SEK 0.50 per share which means that Medivir receives issue proceeds of SEK 45 million before deductions of costs attributable to the issue. For more information about the directed issue, see the separate press release published on 5 February 2026.
For additional information, please contact;
Magnus Christensen Chief Financial Officer Medivir AB
M: +46 8 5468 3100
Email: [email protected]
About Medivir
Medivir develops innovative drugs with a focus on diseases where medical needs are significant. The company focuses on indication areas where available treatment methods are limited or lacking and where there is great potential to offer significant improvements to patients. Collaborations and partnerships are an important part of Medivir's business model, and drug development is conducted either in-house or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm, on the Small Cap list.